These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 27009258)

  • 21. Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study.
    Zwan MD; Rinne JO; Hasselbalch SG; Nordberg A; Lleó A; Herukka SK; Soininen H; Law I; Bahl JM; Carter SF; Fortea J; Blesa R; Teunissen CE; Bouwman FH; van Berckel BN; Visser PJ
    Neurology; 2016 Jan; 86(1):50-8. PubMed ID: 26468410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
    Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers.
    Roe CM; Ances BM; Head D; Babulal GM; Stout SH; Grant EA; Hassenstab J; Xiong C; Holtzman DM; Benzinger TLS; Schindler SE; Fagan AM; Morris JC
    Brain; 2018 Nov; 141(11):3233-3248. PubMed ID: 30304397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease.
    Boerwinkle AH; Wisch JK; Chen CD; Gordon BA; Butt OH; Schindler SE; Sutphen C; Flores S; Dincer A; Benzinger TLS; Fagan AM; Morris JC; Ances BM
    Neurology; 2021 Jul; 97(1):e76-e87. PubMed ID: 33931538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.
    Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C
    J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longitudinal Relationships of White Matter Hyperintensities and Alzheimer Disease Biomarkers Across the Adult Life Span.
    Luo J; Ma Y; Agboola FJ; Grant E; Morris JC; McDade E; Fagan AM; Benzinger TLS; Hassenstab J; Bateman RJ; Perrin RJ; Gordon BA; Goyal M; Strain JF; Yakushev I; Day GS; Xiong C;
    Neurology; 2023 Jul; 101(2):e164-e177. PubMed ID: 37202169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
    Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
    J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
    Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
    J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease.
    Wang L; Benzinger TL; Hassenstab J; Blazey T; Owen C; Liu J; Fagan AM; Morris JC; Ances BM
    Neurology; 2015 Mar; 84(12):1254-60. PubMed ID: 25716355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
    J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls.
    Scheinin NM; Aalto S; Koikkalainen J; Lötjönen J; Karrasch M; Kemppainen N; Viitanen M; Någren K; Helin S; Scheinin M; Rinne JO
    Neurology; 2009 Oct; 73(15):1186-92. PubMed ID: 19726751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study.
    Degerman Gunnarsson M; Lindau M; Wall A; Blennow K; Darreh-Shori T; Basu S; Nordberg A; Larsson A; Lannfelt L; Basun H; Kilander L
    Dement Geriatr Cogn Disord; 2010; 29(3):204-12. PubMed ID: 20332638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease.
    Llibre-Guerra JJ; Li Y; Schindler SE; Gordon BA; Fagan AM; Morris JC; Benzinger TLS; Hassenstab J; Wang G; Allegri R; Berman SB; Chhatwal J; Farlow MR; Holtzman DM; Jucker M; Levin J; Noble JM; Salloway S; Schofield P; Karch C; Fox NC; Xiong C; Bateman RJ; McDade E
    JAMA Netw Open; 2019 Dec; 2(12):e1917126. PubMed ID: 31825500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report.
    Cairns NJ; Ikonomovic MD; Benzinger T; Storandt M; Fagan AM; Shah AR; Reinwald LT; Carter D; Felton A; Holtzman DM; Mintun MA; Klunk WE; Morris JC
    Arch Neurol; 2009 Dec; 66(12):1557-62. PubMed ID: 20008664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pittsburgh compound B-negative dementia: a possibility of misdiagnosis of patients with non-alzheimer disease-type dementia as having AD.
    Shimada H; Ataka S; Takeuchi J; Mori H; Wada Y; Watanabe Y; Miki T
    J Geriatr Psychiatry Neurol; 2011 Sep; 24(3):123-6. PubMed ID: 21750305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
    Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
    JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab.
    Russu A; Samtani MN; Xu S; Adedokun OJ; Lu M; Ito K; Corrigan B; Raje S; Liu E; Brashear HR; Styren S; Hu C
    J Alzheimers Dis; 2016 May; 53(2):535-46. PubMed ID: 27163805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data.
    Guhra M; Thomas C; Boedeker S; Kreisel S; Driessen M; Beblo T; Ohrmann P; Toepper M
    Exp Gerontol; 2016 Jan; 73():107-13. PubMed ID: 26585048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.